Sofinnova leads €4m seed round for Enthera

JDRF T1D Fund, a VC vehicle managed by the US-based Juvenile Diabetes Research Foundation, also took part in the round alongside existing investor BiovelocITA.

Unquote understands that Sofinnova's managing partner Graziano Seghezzi will join Enthera's board to support the startup in this new phase of development.

Enthera will use the fresh capital to move its diabetes ENT-001 programme to a proof-of-concept pre-clinical stage and further develop its research in the regenerative medicine sector.

Unquote understands that Sofinnova deployed capital from its Sofinnova Capital VIII fund, which held a final close on €300m in December 2015, exceeding its €250m target.

Previous funding
Enthera received €1.5m from BiovelocITA in 2016 to start its research programme.

Company
Founded in 2016 as a spinout from the startup accelerator BiovelocITA, Milan-based Enthera is a biotech startup dedicated to researching new therapeutic approaches for type 1 diabetes and gastrointestinal pathologies.

People
Sofinnova Partners – Graziano Seghezzi (managing partner).
Enthera – Paolo Fiorina (co-founder; chief scientific officer); Silvano Spinelli (president).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Southern Europe
• Healthcare
• Sofinnova Partners
• Italy
• Venture